Retransplantation for hepatic allograft failure: Prognostic modeling and ethical considerations

Liver Transplantation

Volumn 8, Issue 4, 2002, Pages 313-322

  Biggins, Scott W ^a,b   Beldecos, Athena ^a,b   Rabkin, John M ^a,b   Rosen, Hugo R ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGRAFT; CONTROLLED STUDY; GRAFT FAILURE; GRAFT SURVIVAL; HEALTH CARE COST; HUMAN; LIVER TRANSPLANTATION; MEDICAL ETHICS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; REOPERATION; REVIEW; STATISTICAL MODEL; TREATMENT INDICATION;

EID: 0036250288     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2002.31746     Document Type: Article

References (57)

1. Liver transplantation: Current status and novel approaches to liver replacement
2. The need for a consensus agreement on indications of liver transplantation
3. Liver transplantation
4. Recurrent disease after liver transplantation: Implications for the future
5. Understanding "marginal" liver grafts
6. Primary nonfunction of the liver graft: When should we retransplant?
7. The significance of early aminotransferase elevation following liver transplantation
8. Disease recurrence following liver transplantation
9. Alcohol use after liver transplantation in alcoholics: A clinical cohort follow-up study
10. The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: A pilot study
11. HCV-related fibrosis progression following liver transplantation: Increase in recent years
12. + response to hepatitis C and severity of recurrence after transplantation
13. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes
14. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: Results of the National Institute of Diabetes and Digestive and Kidney Disease Liver Transplantation Database
15. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation
16. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients
17. Alcohol injury in the transplanted liver
18. Efficacy of liver transplantation for alcoholic cirrhosis with respect to recidivism and compliance
19. Liver transplantation for patients with alcoholism and end-stage liver disease
20. The prevalence, rate of onset and spectrum of histologic liver disease in alcohol abusing liver allograph recipients
21. Recurrence of primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis
22. Primary cholestatic liver disease may recur after liver transplant
23. Recurrence of primary sclerosing cholangitis following liver transplantation
24. Primary biliary cirrhosis: Histological evidence of disease recurrence after liver transplantation
25. Recurrence of autoimmune hepatitis following liver transplantation
26. Recurrence of autoimmune hepatitis after liver transplantation
27. Retransplantation in hepatitis B: A multicenter experience
28. Liver transplantation for hepatitis B virus-associated cirrhosis: A progress report
29. Retransplantation of patients with severe posttransplant hepatitis B in the first allograft
30. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy
31. Socioeconomic aspects of hepatic transplantation
32. Liver transplant candidate stratification systems: Implications for third-party payors and organ allocation
33. Liver transplantation
34. Prognostic value of Child-Turcotte criteria in medically treated cirrhosis
35. Prognosis and life expectancy in chronic liver disease
36. Hepatic retransplantation in cholestatic liver disease: Impact of the interval to retransplantation on survival and resource utilization
37. Clinical characteristics affecting the outcomes of liver retransplantation
38. Hepatic retransplantation: An analysis of risk factors associated with outcome
39. A simple model to estimate survival after retransplantation of liver
40. A model to predict survival following hepatic retransplantation
41. Hepatitis C infection in patients undergoing liver retransplantation
42. A model to predict survival in patients with end-stage liver disease
43. Predicting the prognosis of chronic liver disease. An evolution from Child to MELD
44. Validation of a survival model following liver transplantation (ReTx): Use of an international cohort
45. A prognostic model for the outcome of liver transplantation in patients with cholestatic liver disease
46. An economic analysis of liver transplantation costs, insurance coverage, and reimbursement
47. Analysis of waiting times
48. Rationing failure: The ethical lessons of the retransplantation of scarce vital organs
49. Assessing priorities for allocation of donor liver grafts: Survey of public and clinicians
50. Is retransplantation cost effective?
51. Hepatic retransplantation in New England-A regional experience and survival model
52. Live donor liver transplantation
53. Right lobe living donor liver transplantation: A review
54. Retransplantation for hepatitis C: Implications of different policies
55. Reexamining organ transplantation